Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Cash from Financing Activities (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Cash from Financing Activities for 16 consecutive years, with -$3.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 102.19% to -$3.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$14.5 million, a 109.2% decrease, with the full-year FY2025 number at -$14.5 million, down 109.2% from a year prior.
  • Cash from Financing Activities was -$3.6 million for Q4 2025 at Lemaitre Vascular, down from -$2.9 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $164.1 million in Q4 2024 to a low of -$10.5 million in Q2 2021.
  • A 5-year average of $7.0 million and a median of -$2.6 million in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: soared 6208.75% in 2024, then crashed 13533.33% in 2025.
  • Lemaitre Vascular's Cash from Financing Activities stood at -$1.2 million in 2021, then crashed by 83.09% to -$2.1 million in 2022, then fell by 26.58% to -$2.7 million in 2023, then skyrocketed by 6208.75% to $164.1 million in 2024, then plummeted by 102.19% to -$3.6 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Cash from Financing Activities are -$3.6 million (Q4 2025), -$2.9 million (Q3 2025), and -$2.8 million (Q2 2025).